Sara Crawford1, Sheree L Boulet2, Jennifer F Kawwass3, Denise J Jamieson2, Dmitry M Kissin2. 1. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: sgv0@cdc.gov. 2. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University, Atlanta, Georgia.
Abstract
OBJECTIVE: To compare characteristics, explore predictors, and compare assisted reproductive technology (ART) cycle, transfer, and pregnancy outcomes of autologous and donor cryopreserved oocyte cycles with fresh oocyte cycles. DESIGN: Retrospective cohort study from the National ART Surveillance System. SETTING: Fertility treatment centers. PATIENT(S): Fresh embryo cycles initiated in 2013 utilizing embryos created with fresh and cryopreserved, autologous and donor oocytes. INTERVENTION(S): Cryopreservation of oocytes versus fresh. MAIN OUTCOMES MEASURE(S): Cancellation, implantation, pregnancy, miscarriage, and live birth rates per cycle, transfer, and/or pregnancy. RESULT(S): There was no evidence of differences in cancellation, implantation, pregnancy, miscarriage, or live birth rates between autologous fresh and cryopreserved oocyte cycles. Donor cryopreserved oocyte cycles had a decreased risk of cancellation before transfer (adjusted risk ratio [aRR] 0.74, 95% confidence interval [CI] 0.57-0.96) as well as decreased likelihood of pregnancy (aRR 0.88, 95% CI 0.81-0.95) and live birth (aRR 0.87, 95% CI 0.80-0.95); however, there was no evidence of differences in implantation, pregnancy, or live birth rates when cycles were restricted to those proceeding to transfer. Donor cryopreserved oocyte cycles proceeding to pregnancy had a decreased risk of miscarriage (aRR 0.75, 95% CI 0.58-0.97) and higher live birth rate (aRR 1.05, 95% CI 1.01-1.09) with the transfer of one embryo, but higher miscarriage rate (aRR 1.28, 95% CI 1.07-1.54) and lower live birth rate (aRR 0.95, 95% CI 0.92-0.99) with the transfer of two or more. CONCLUSION(S): There was no evidence of differences in ART outcomes between autologous fresh and cryopreserved oocyte cycles. There was evidence of differences in per-cycle and per-pregnancy outcomes between donor cryopreserved and fresh oocyte cycles, but not in per-transfer outcomes. Published by Elsevier Inc.
OBJECTIVE: To compare characteristics, explore predictors, and compare assisted reproductive technology (ART) cycle, transfer, and pregnancy outcomes of autologous and donor cryopreserved oocyte cycles with fresh oocyte cycles. DESIGN: Retrospective cohort study from the National ART Surveillance System. SETTING: Fertility treatment centers. PATIENT(S): Fresh embryo cycles initiated in 2013 utilizing embryos created with fresh and cryopreserved, autologous and donor oocytes. INTERVENTION(S): Cryopreservation of oocytes versus fresh. MAIN OUTCOMES MEASURE(S): Cancellation, implantation, pregnancy, miscarriage, and live birth rates per cycle, transfer, and/or pregnancy. RESULT(S): There was no evidence of differences in cancellation, implantation, pregnancy, miscarriage, or live birth rates between autologous fresh and cryopreserved oocyte cycles. Donor cryopreserved oocyte cycles had a decreased risk of cancellation before transfer (adjusted risk ratio [aRR] 0.74, 95% confidence interval [CI] 0.57-0.96) as well as decreased likelihood of pregnancy (aRR 0.88, 95% CI 0.81-0.95) and live birth (aRR 0.87, 95% CI 0.80-0.95); however, there was no evidence of differences in implantation, pregnancy, or live birth rates when cycles were restricted to those proceeding to transfer. Donor cryopreserved oocyte cycles proceeding to pregnancy had a decreased risk of miscarriage (aRR 0.75, 95% CI 0.58-0.97) and higher live birth rate (aRR 1.05, 95% CI 1.01-1.09) with the transfer of one embryo, but higher miscarriage rate (aRR 1.28, 95% CI 1.07-1.54) and lower live birth rate (aRR 0.95, 95% CI 0.92-0.99) with the transfer of two or more. CONCLUSION(S): There was no evidence of differences in ART outcomes between autologous fresh and cryopreserved oocyte cycles. There was evidence of differences in per-cycle and per-pregnancy outcomes between donor cryopreserved and fresh oocyte cycles, but not in per-transfer outcomes. Published by Elsevier Inc.
Authors: Kate Devine; Sunni L Mumford; Kara N Goldman; Brooke Hodes-Wertz; Sarah Druckenmiller; Anthony M Propst; Nicole Noyes Journal: Fertil Steril Date: 2015-03-23 Impact factor: 7.329
Authors: M Solé; J Santaló; M Boada; E Clua; I Rodríguez; F Martínez; B Coroleu; P N Barri; A Veiga Journal: Hum Reprod Date: 2013-06-05 Impact factor: 6.918
Authors: L Parmegiani; G E Cognigni; S Bernardi; S Cuomo; W Ciampaglia; F E Infante; C Tabarelli de Fatis; A Arnone; A M Maccarini; M Filicori Journal: Reprod Biomed Online Date: 2011-07-13 Impact factor: 3.828
Authors: Lisa M Pastore; Mindy S Christianson; Bailey McGuinness; Kamaria Cayton Vaught; Jacqueline Y Maher; William G Kearns Journal: Reprod Biomed Online Date: 2018-12-10 Impact factor: 3.828
Authors: V E Klenov; S L Boulet; R B Mejia; D M Kissin; E Munch; A Mancuso; B J Van Voorhis Journal: J Assist Reprod Genet Date: 2018-06-21 Impact factor: 3.412
Authors: Jessica Cremonese; Marianna Marcon; Laura Oppi; Giulia Paletti; Vincenzo Romolo; Pamela Tozzo; Luciana Caenazzo Journal: Int J Environ Res Public Health Date: 2022-02-18 Impact factor: 3.390
Authors: Lorraine S Kasaven; Srdjan Saso; Natalie Getreu; Helen O'Neill; Timothy Bracewell-Milnes; Fevzi Shakir; Joseph Yazbek; Meen-Yau Thum; James Nicopoullos; Jara Ben Nagi; Paul Hardiman; Cesar Diaz-Garcia; Benjamin P Jones Journal: Hum Reprod Date: 2022-08-25 Impact factor: 6.353